Volume 7.31 | Aug 13

Mammary Cell News 7.31 August 13, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
 
TOP STORY
Common Breast Cancer Mutation Induces Multipotency and Tumor Heterogeneity
Researchers have shown how a common breast cancer mutation can lead to tumor heterogeneity. They used in situ genetic lineage tracing to unravel the potential of PIK3CAH1047R to induce tumor heterogeneity. [Press release from Friedrich Miescher Institute for Biomedical Research discussing online prepublication in Nature] Press Release | Abstract
Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Reactivation of Multipotency by Oncogenic PIK3CA Induces Breast Tumor Heterogeneity
Concomitant deletion of p53 and expression of Pik3caH1047R accelerated tumor development and induced more aggressive mammary tumors. Expression of Pik3caH1047R in unipotent basal cells gave rise to luminal-like cells, while its expression in unipotent luminal cells gave rise to basal-like cells before progressing into invasive tumors. [Nature] Abstract | Press Release

The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis
Investigators showed that depletion of the inositol polyphosphate 5-phosphatase PIPP increases breast cancer cell transformation, but reduces cell migration and invasion. Pipp ablation accelerates oncogene-driven breast cancer tumor growth in vivo, but paradoxically reduces metastasis by regulating AKT1-dependent tumor cell migration. [Cancer Cell] Abstract | Graphical Abstract | Press Release

Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage–Derived VEGFA
VEGFA signaling from TIE2hi tumor microenvironment of metastasis macrophages causes local loss of vascular junctions, transient vascular permeability, and tumor cell intravasation, demonstrating a role for the TMEM within the primary mammary tumor. [Cancer Discov] Abstract | Press Release

Genome-Wide Lentiviral ShRNA Screen Identifies Serine/Arginine-Rich Splicing Factor 2 as a Determinant of Oncolytic Virus Activity in Breast Cancer Cells
The authors used a pooled genome-wide short hairpin RNA library and found that depletion of the splicing factor arginine-rich splicing factor 2 leads to enhanced cytotoxicity of breast cancer cells by KM100. [Oncogene] Abstract

miR-378a-3p Modulates Tamoxifen Sensitivity in Breast Cancer MCF-7 Cells through Targeting GOLT1A
Investigators found that miR-378a-3p expression was downregulated in tamoxifen-resistant (TamR) and long-term estrogen-deprived cells as well as in clinical breast cancer tissues. GOLT1A was overexpressed in breast cancer specimens and GOLT1A-specific siRNAs inhibited the growth of TamR cells. [Sci Rep] Full Article

Rhus coriaria Induces Senescence and Autophagic Cell Death in Breast Cancer Cells through a Mechanism Involving p38 and ERK1/2 Activation
Scientists investigated the anticancer effect of Rhus coriaria on three breast cancer cell lines. They demonstrated that Rhus coriaria ethanolic extract inhibits the proliferation of these cell lines in a time- and concentration-dependent manner. [Sci Rep] Full Article

PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer
Researchers observed that PEAK1 expression was highest in mesenchymal breast cancer cells, correlated with migration potential and increased in response to transforming growth factor β (TGFβ)-induced epithelial-mesenchymal transition. [PLoS One] Full Article

MCF-7 Human Breast Cancer Cells Form Differentiated Microtissues in Scaffold-Free Hydrogels
When compared to MCF-7 cells cultured in two-dimensional monolayer culture, MCF-7 microtissues exhibit increased mRNA expression of luminal epithelial markers keratin 8 and keratin 19 and decreased expression of basal marker keratin 14 and the mesenchymal marker vimentin [PLoS One] Full Article

Activin-A Signaling Promotes Epithelial–Mesenchymal Transition, Invasion, and Metastatic Growth of Breast Cancer
Investigators evaluated the status and role of Activin-A signaling pathway in breast tumors. Activin-A promoted anchorage-independent growth, epithelial–mesenchymal transition, invasion, angiogenesis, and stemness of breast cancer cells. [npj Breast Cancer] Full Article

CLINICAL RESEARCH

HAGE in Triple Negative Breast Cancer (TNBC) Is a Novel Prognostic, Predictive and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis
HAGE protein expression was investigated in an early primary TNBC cohort who received adjuvant chemotherapy (ACT) and in a locally advanced primary TNBC cohort who received anthracycline-combination Neo-ACT. [Clin Cancer Res] Abstract | Press Release

Phase I Trial of Afatinib plus Vinorelbine in Japanese Patients with Advanced Solid Tumors, Including Breast Cancer
Investigators assessed afatinib, an irreversible ErbB family blocker, plus vinorelbine in Japanese patients with advanced solid tumors not amenable to standard treatment. [Cancer Chemother Pharmacol] Abstract

 
REVIEWS
Targeting BCL-2 to Enhance Vulnerability to Therapy in Estrogen Receptor-Positive Breast Cancer
The authors summarize the current understanding of the role of BCL-2 and its family members in mammary gland development and breast cancer, recent progress in the development of new BH3 mimetics as well as their potential for targeting estrogen receptor-positive breast cancer. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
Merck and MD Anderson Announce Immuno-Oncology Research Collaboration in Solid Tumors
Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA®, in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines. [The University of Texas MD Anderson Cancer Center] Press Release

Newcastle Gets £5 Million to Boost Drug Development
Cancer Research UK’s Drug Discovery Committee has awarded Newcastle University’s Northern Institute of Cancer Research £5 million to bring more cancer drugs to clinical trials. [Cancer Research UK] Press Release

UNM Cancer Center Awarded National Cancer Institute’s Highest Comprehensive Designation
The University of New Mexico (UNM) Cancer Center has been awarded the highest designation and rating in the United States for cancer treatment and research programs. It has received the National Cancer Institute’s “NCI Comprehensive Cancer Center” designation, identifying it as one of the leading cancer centers in the nation and the only such cancer center in New Mexico. [The University of New Mexico] Press Release

National Award for Queen’s Cancer Researchers
Cancer experts from Queen’s University Belfast have received a major award exceeding £3.6 million from Cancer Research UK aimed at developing a national digital pathology program to assist and accelerate the delivery of precision medicine in the UK. [Queen’s University Belfast] Press Release

Geoffrey Wahl Named a National Cancer Institute Outstanding Investigator Award Recipient to Further His Cancer Research
Salk Professor Geoffrey Wahl will receive the National Cancer Institute Outstanding Investigator Award, which encourages cancer research with breakthrough potential. Wahl, a professor in Salk’s Gene Expression Laboratory, will receive $7.9 million over a seven-year period to further his cancer research. [Salk Institute for Biological Studies] Press Release

From our sponsor:
Attend STEMCELL Technologies’ Mammary Stem Cells Training Course on October 6-7 in Vancouver.
Master the techniques of mouse mammary tissue dissection, mammary fat pad clearing, estrus staging of mice, transplantation to the renal capsule and more. Lectures and hands-on training will be led by Dr. John Stingl, a leading researcher in the field of mammary biology. Limited spaces available.
Apply Today!
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW The Presence and Future of the RAS Pathway: From Function and Genomics to Inhibition
October 5-7, 2015
Pamplona, Spain

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Cancer Biology (National Cancer Institute)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Researcher – Translational Breast Cancer Research (Dublin City University)

Postdoctoral Position – Cancer Biology (Northwestern University)

Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Postdoctoral Fellow – Cancer Research (National University of Singapore)

Senior Product Manager – Breast Cancer (Celgene Corporation)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate/Assistant Professor – Breast Cancer (University of Chicago)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us